4 news items
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
SYRS
14 May 24
tamibarotene and deliver benefit to patients, and the sufficiency of Syros' capital resources to fund its operating expenses and capital expenditure
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
SYRS
9 Apr 24
tamibarotene and deliver benefit to patients, and the potential benefits of receiving Fast Track designation. The words "anticipate," "believe," "continue
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
SYRS
27 Mar 24
tamibarotene and deliver benefit to patients, and the sufficiency of Syros' capital resources to fund its operating expenses and capital expenditure
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
SYRS
25 Mar 24
of its clinical trials, the timing to report clinical data, and the ability to commercialize tamibarotene and deliver benefit to patients. The words
- Prev
- 1
- Next